Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, October 8, 2026 – Life Biosciences (“Life Bio”), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results